Gedatolisib (PF-05212384, PKI-587),双重PI 3-K / mTOR抑制剂

Gedatolisib (PF-05212384, PKI-587) (订货以英文为准)

编号:P129530
CAS号:1197160-78-3
分子式:C32H41N9O4
分子量:615.73
货号 品牌 包装 目录价 您的价格 库存 数量 购买
P129530-5mg 阿拉丁 5mg ¥225.90
P129530-50mg 阿拉丁 50mg ¥1440.90
P129530-10mg 阿拉丁 10mg ¥360.90
产品名称 Gedatolisib (PF-05212384, PKI-587)
中文名称 Gedatolisib (PF-05212384, PKI-587),双重PI 3-K / mTOR抑制剂
CAS号 1197160-78-3
分子式(M.F.) C32H41N9O4
分子量(M.W.) 615.73
储存条件 -20°C储存
溶解性DMSO 2 mg/mL Water <1 mg/mL Ethanol <1 mg/mL
存贮条件储存温度-20°C
应用A PI3K and FRAP inhibitor
产品介绍Gedatolisib (PF-05212384, PKI-587)是一种高度有效的,双重PI3Kα, PI3Kγ和mTOR抑制剂,IC50分别为0.4 nM, 5.4 nM和1.6 nM。
备注PKI-587 is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Phase 2.
生化机理PKI-587 is a potent inhibitor to PI3K-α, PI3K-γ, and mTOR (FRAP) with IC50 of 0.4 nM, 5.4 nM, and 1.6 nM, respectively. PKI-587 also exhibits potency against the most frequently occurring mutant forms of PI3Kα, notably the H1047R and E545K with IC50 of 0.6 nM and 0.6 nM, respectively. PF-05212384 inhibitory actions against PI3Ks and mTORs causes tumor cell growth inhibition in MDA-361 and PC3-MM2 cell lines with IC50 of 4 nM and 13.1 nM, respectively.
别名N-[4-[[4-(二甲基氨基)-1-哌啶基]羰基]苯基]-N'-[4-[4,6-二(4-吗啉基)-1,3,5-三嗪-2-基]苯基]脲;PKI-587;Gedatolisib; PF-05212384;PKI-587;N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea
搜索质检报告(COA)
搜索MSDS
相关产品
CAS号:252917-06-9
¥ 113.90 C125082-5mg
CAS号:252935-94-7
¥ 735.90 C129718-5mg
¥ 502.90 C129710-5mg
CAS号:1217486-61-7
¥ 109.90 B127311-1mg
CAS号:371935-74-9
¥ 552.90 P125961-10mg
CAS号:1173900-33-8
¥ 627.90 A129523-5mg
CAS号:900185-02-6
¥ 152.90 P129553-1mg
CAS号:915019-65-7
¥ 277.90 B126286-25mg
CAS号:552325-16-3
¥ 1299.90 A126060-5mg